



Myrexis to Hold Conference Call to Discuss First Quarter 2012 Financial Results

SALT LAKE CITY, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Wednesday, November 9, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for its fiscal first quarter 2012 ended September 30, 2011.

The conference call will be hosted by Robert Lollini, President and Chief Executive Officer, and Andrea Kendell, Chief Financial Officer.

To participate, please dial (877) 312-5447 (U.S.) or (253) 237-1129 (International); Conference ID: 21598836. To access the live webcast please visit the Investor Relations section on the corporate website at www.myrexis.com.

A replay of the conference call will be available beginning November 9, 2011 at 7:30 p.m. ET (4:30 p.m. PT) and ending on December 9, 2011 by dialing toll-free in the U.S. (855) 859-2056 or (800) 585-8367 and (404) 537-3406 for international callers, Conference ID: 21598836. A replay of the webcast will also be available on the corporate website for one month, through December 9, 2011.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.

Additional information about Myrexis is available through its corporate website, www.myrexis.com.

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=9929>

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2011, which was filed with the Securities and Exchange Commission on September 13, 2011, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Wayne Laslie

Chief Operating Officer

801-214-7822

investor.relations@myrexis.com

The Ruth Group

Stephanie Carrington/Joshua Drumm, PhD (investors)

(646) 536-7017 / (646) 536-7006

scarrington@theruthgroup.com/

jdrumm@theruthgroup.com

Victoria Aguiar (media)

(646) 536-7013

vaguiar@theruthgroup.com